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To determine the distribution and antimicrobial drug resistance in bacterial pathogens causing nosocomial
infections, surveillance data on nosocomial infections documented from 1981 to 1999 at National Taiwan Uni-
versity Hospital were analyzed. During this period, 35,580 bacterial pathogens causing nosocomial infections
were identified. Candida species increased considerably, ranking first by 1999 in the incidence of pathogens
causing all nosocomial infections, followed by Staphylococcus aureus and Pseudomonas aeruginosa. Can-
dida species also increased in importance as bloodstream infection isolates, from 1.0% in 1981-1986 to
16.2% in 1999. The most frequent isolates from urinary tract infections were Candida species (23.6%), fol-
lowed by Escherichia coli (18.6%) and P. aeruginosa (11.0%). P. aeruginosa remained the most frequent iso-
lates for respiratory tract and surgical site infections in the past 13 years. A remarkable increase in incidence
was found in methicillin-resistant S. aureus (from 4.3% in 1981-1986 to 58.9% in 1993-1998), cefotaxime-
resistant E. coli (from 0% in 1981-1986 to 6.1% in 1993-1998), and cefotaxime-resistant Klebsiella pneumo-
niae  (from 4.0% in 1981-1986 to 25.8% in 1993-1998). Etiologic shifts in nosocomial infections and an
upsurge of antimicrobial resistance among these pathogens, particularly those isolated from intensive care
units, are impressive and alarming.  
he emergence of resistance to antimicrobial agents is a glo-
bal public health problem, particularly in pathogens caus-
ing nosocomial infections (1-5). Antimicrobial resistance
results in increased illness, deaths, and health-care costs (1,2,6-
10). The distribution of pathogens causing nosocomial infec-
tions, especially antimicrobial-resistant pathogens, changes
with time and varies among hospitals and among different
locations in the same hospital (11-15). The increasing number
of immunocompromised patients and increased use of indwell-
ing devices, as well as widespread use of antimicrobial agents
in hospital settings, particularly in intensive care units (ICUs),
contributes to antimicrobial resistance among pathogens caus-
ing nosocomial infections (1,4,6,10).
Surveillance data reported by the National Nosocomial
Infections Surveillance (NNIS) System for 1993-1997 com-
pared with January-November 1998 show a continuing
increase in antimicrobial-resistant pathogens associated with
nosocomial infections in ICU patients from U.S. hospitals (2).
The increase is particularly marked for vancomycin-resistant
enterococci (VRE) (55%), methicillin-resistant Staphylococcus
aureus (MRSA) (31%), third-generation cephalosporin-resis-
tant Escherichia coli (29%), imipenem-resistant Pseudomonas
aeruginosa (32%), and quinolone-resistant  P. aeruginosa
(89%) (2). Studies since 1990 have clearly demonstrated that
Candida species continue to be an important cause of nosoco-
mial infections, particularly of bloodstream infections (BSI).
Furthermore, the proportion of BSI caused by Candida species
other than C. albicans is increasing (14,16-20). 
We describe the distribution of major bacterial pathogens
causing nosocomial infections from 1981 to 1999 in National
Taiwan University Hospital and demonstrate the emergence of
antimicrobial drug resistance among these pathogens during
this period. 
Materials and Methods
Data Collection
National Taiwan University Hospital is a 2,000-bed tertiary
referral center in Taipei, northern Taiwan. Available data for
inpatient-days at the hospital ranged from 294,946 in 1990 to
566,165 in 1999. The number of ICU beds increased from 40-
50 before 1993 to 100-120 in 1998-99. The Nosocomial Infec-
tion Control Committee of the hospital was established in 1980
to identify pathogens causing nosocomial infections and to
obtain and analyze antimicrobial susceptibility results of these
pathogens from the hospital’s clinical microbiology laboratory.
NNIS definitions were used for nosocomial infections (e.g.,
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bloodstream; respiratory tract, including lower respiratory tract
and pneumonia; urinary tract; and surgical site infections)
(21,22). Isolates were considered nosocomial if the culture was
dated >2 days after admission. All isolates were identified by
standard methods and confirmed by using Vitek or API prod-
ucts (bioMerieux Vitek, Inc., Hazelwood, MO). For determin-
ing the percentage of resistance, the same organisms from
multiple blood cultures or from the same sources with identical
antibiotype were considered a single isolate. The amount of
use for each indicated antimicrobial agent (including oral and
parenteral forms) was expressed in grams per 1,000 inpatient-
days.
Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing of the bacterial isolates
was performed by the disk diffusion method as described by
the National Committee for Clinical Laboratory Standards
(NCCLS) (23). S. aureus ATCC 25923, E. coli ATCC 25922,
and  P. aeruginosa ATCC 27853 were included as control
strains. Interpretive criteria for susceptibility or resistance fol-
lowed NCCLS guidelines (23). For this report, we present sus-
ceptibility data for penicillin, oxacillin, vancomycin,
gentamicin, cefotaxime, ceftazidime, imipenem, and ciproflox-
acin. The susceptibility data for imipenem and ciprofloxacin
were available only since 1993; those for other agents were
available from 1981 to 1999. 
Antifungal susceptibility testing of amphotericin B and flu-
conazole against 150 blood isolates of Candida species col-
lected from October 1997 to September 1999 was performed
by the E test (AB BIODISK, Solna, Sweden) according to the
manufacturer’s instructions. Quality control was performed by
testing C. parapsilosis ATCC 2019 and C. krusei ATCC 6258.
MIC results were interpreted in accordance with NCCLS
guidelines (24).
Results
During the 19-year period, 35,580 bacterial pathogens
causing nosocomial infections were identified. The hospital’s
overall rate of nosocomial infections during the 19-year period
ranged from 3.9% to 6.1%. For the four major sites of nosoco-
mial infections, data are presented as numbers of infection per
10,000 patient-days from 1991 to 1999 (Figure 1). BSI ranked
first in nosocomial infection sites in 1999, followed by urinary
tract, surgical site, and respiratory tract infections.
Data for the catheter- and ventilator-days of the hospital-
ized patients were not available. However, the mean percent-
ages of patients who stayed in ICUs (six medical ICUs and six
surgical ICUs) and used urinary catheters, arterial and central
venous catheters, and ventilators were 75.0%, 77.9%, 63.2%,
respectively, in 1996 and 79.4%, 81.4%, and 65.2%, respec-
tively, in 1999. The incidence (number of infections/patient-
days x 1,000) of urinary catheter-related urinary tract infection,
vascular catheter-associated BSI, and ventilator-associated
pneumonia in the ICUs was 4.4, 5.6, and 2.7, respectively, in
1996 and 6.0, 7.1, and 3.4, respectively, in 1999.
Gram-negative bacteria remained the predominant patho-
gens (66.1% in 1981, 51.3% in 1993, and 53.4% in 1999);
however, incidences of fungal infections have increased
recently (Table 1). In a comparison of data grouped into four
time periods (1981-1986, 1987-1992, 1993-1998, and 1999),
E. coli decreased from 12.1% of all nosocomial infections in
1981-1986 to 9.5% in 1993-1998; however, infections caused
by  S. aureus increased from 5.2% (1981-1986) to 12.1%
(1993-1998). Candida species showed a considerable increase
(from 3.7% in 1981-1986 to 16.2% in 1999) and have ranked
first since 1993, followed by  S. aureus and  P. aeruginosa
(Table 1). 
Candida species,  S. aureus,  and  Acinetobacter species
were also important bloodstream isolates (Table 1), increasing
from 1.0%, 5.2%, and 6.1%, respectively, in 1981-1986 to
16.2%, 13.0%, and 7.6%, respectively, in 1999. Although E.
coli was also a frequent isolate, it declined in percentage of all
BSI from 18.7% in 1981-1986 to 9.0% in 1999. Other patho-
gens declining in percentage of BSI from 1981-1986 to 1999
included K. pneumoniae, P. aeruginosa, and Enterococcus spe-
cies. 
From 1992 to 1999, 1,065 isolates of Candida species were
recovered from patients with nosocomial BSIs.  C. glabrata
(8.8%) ranked fourth in incidence behind C. albicans (59.3%),
C. tropicalis (17.6%), and  C. parapsilosis (8.2%)  in 1999.
Only four blood isolates of C. krusei were identified during the
8-year period.
The most frequent isolates from urinary tract infections in
1993-1998 were Candida species (23.6%), followed by E. coli
(18.6%) and P. aeruginosa (11.0%). However, in 1999, E. coli
(18.4%) replaced Candida species (14.3%) as the top-ranking
pathogen causing urinary tract infections. P. aeruginosa
remained the most frequent isolate for respiratory tract and sur-
gical site infections in the past 13 years.  Candida species
increased in incidence in surgical site infections, from 1.8% in
1981-1986 to 6.4% in 1999. Among pathogens causing respira-
tory tract infections,  Acinetobacter species ranked fifth in
Figure 1. Rates of four major nosocomial infections expressed as num-
ber of infections per 10,000 patient-days at National Taiwan University
Hospital from 1991 to 1999. BSI, bloodstream infection; UTI, urinary
tract infection; SSI, surgical site infection; RTI, respiratory tract infec-
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1993-1998 (9.3%) but second in 1999 (13.0%); Candida spe-
cies accounted for only 2.2% in 1999. 
The distributions of selected antimicrobial drug-resistant
pathogens causing all nosocomial infections and BSIs of
patients hospitalized in intensive care units or general wards is
shown in Table 2. Antimicrobial drug-resistant pathogens caus-
ing BSIs that increased markedly over the study period were
methicillin-resistant S. aureus (4.3% in 1981-1986, 58.9% in
1993-1998, and 69.2% in 1999), cefotaxime-resistant E. coli
(0% in 1981-1986, 6.1% in 1993-1998, and 12.5% in 1999),
and cefotaxime-resistant  Klebsiella pneumoniae  (4.0% in
1981-1986, and 25.8% in 1993-1998). The frequencies of these
three resistant pathogens were considerably higher in isolates
from ICUs than those from general wards (84.6% vs. 48.3%
for MRSA, 17.1% vs. 5.1% for cefotaxime-resistant E. coli,
and 51.1% vs. 18.3% for cefotaxime-resistant K. pneumoniae
in 1993-1998). The incidence of methicillin-resistant coagu-
lase-negative staphylococci (MRCoNS) remained high (72%-
90%) during the 19-year period. 
Ceftazidime use is associated with trends of several antimi-
crobial-resistant pathogens during the period 1991 to 1999
(Figure 2). Restriction of third-generation cephalosporins (par-
ticularly ceftazidime) was implemented in 1997. In 1999, resis-
tance to cefotaxime in K. pneumoniae diminished; however,
resistance to cefotaxime in E. coli and resistance to ceftazidime
in P. aeruginosa slightly increased. 
The first clinical isolate of VRE was recognized in 1995
(25,26). Since then, 80 isolates of VRE (49 of E. faecalis and
31 of  E. faecium) have been recovered from hospitalized
patients. The incidence of VRE in isolates causing nosocomial
infection increased from 1.8% in 1995 to 6.7% in 1997 and
25.2% in 1999 (Figure 3). Among these VRE isolates, 4 were
from blood, 15 from urine, and the rest were pus or drainage
fluid. Only 12 (15%) of these isolates were from patients
admitted to ICUs, and 6 of these 12 isolates were recovered in
1999. The incidence of VRE in enterococci causing nosoco-
mial infections in ICUs was 7.0%. The relationship of increas-
ing vancomycin use and the increase in vancomycin resistance
in enterococci is shown in Figure 3.
The incidences of imipenem-resistant P. aeruginosa (1993
to 1998) and imipenem-resistant  Acinetobacter baumannii
(1999) isolated from ICUs were five- to ten-fold higher than
isolates recovered from non-ICU settings. However, this was
not the case with imipenem-resistant P. aeruginosa in 1999 or
imipenem-resistant A. baumannii in 1993-1998 (Figure 4). 
All 150 isolates of Candida species were inhibited by 1 µg/
mL of amphotericin B (MIC range 0.03 to 1 µg/mL). The
MIC50 and MIC90 of C. glabrata were 16 µg/mL and >32 µg/
mL, respectively. Twenty-one isolates (70%) of C. glabrata
were nonsusceptible to fluconazole (MICs >8 µg/mL). Four
(15.4%) of the C. parapsilosis isolates had MICs >8 µg/mL (2
had MICs 16 µg/mL and the other 2 had MICs 64 µg/mL).
Table 1. Incidences of 10 top-ranking pathogens causing nosocomial infections and infections from four body sites at National Taiwan University
Hospital, 1981 to 1999
Pathogen
% of indicated pathogen causing nosocomial infection (1981-1986/1987-1992/1993-1998/1999)a
All BSI RTI UTI SSI
Candida spp. 3.7/9.1/14.4/16.2 1.0/9.2/16.4/16.2 2.0/5.8/2.1/2.2 8.4/16.0/23.6/14.3 2.4/5.1/5.9/6.4
Staphylococcus 
aureus 5.2/9.1/12.1/12.0 5.2/9.3/11.5/13.0 4.0/8.4/16.9/12.6 1.4/2.6/3.3/2.1 5.5/5.2/13.0/15.4
Pseudomonas 
aeruginosa 12.7/14.0/11.1/11.8 10.0/9.4/7.2/7.8 19.6/21.9/23.8/25.7 11.7/11.2/11.0/10.4 11.1/17.4/14.3/16.0
Escherichia coli 12.1/8.4/9.5/9.9 18.7/9.7/8.7/9.0 4.8/2.4/3.5/3.7 19.1/19.9/18.6/18.4 11.7/5.8/5.8/6.8
Klebsiella 
pneumoniae 8.1/5.5/7.2/6.8 11.6/6.6/7.7/7.0 10.9/9.4/11.5/10.8 9.0/7.0/8.6/8.2 6.9/3.5/4.2/4.6
Enterobacter spp. 6.0/7.6/7.4/6.4 8.0/8.6/7.3/6.9 5.2/8.1/11.8/8.6 9.0/8.4/6.7/6.3 4.5/7.9/7.8/5.5
Enterococcus spp. 8.8/7.8/6.7/6.2 8.7/6.2/6.3/7.6   11.6/9.7/8.1/6.5 10.1/12.6/9.6/7.9
Acinetobacter spp. 4.4/5.1/4.9/5.4 6.1/8.8/7.2/7.6 11.0/13.4/9.3/13.0
CoNS 2.8/6.9/6.6/5.1 2.7/8.5/7.9/4.9 3.2/7.1/9.1/6.8
Other NFGNB 5.7/6.1/4.8/4.1 5.9/7.7/6.8/6.7 12.3/13.1/7.8/8.2 7.4/6.5/4.4/2.8
S. marcescens 3.5/1.9/3.7/4.1
Proteus spp. 3.2/2.2/2.4/1.1 3.8/3.8/3.8/3.7
Citrobacter spp. 5.9/4.4/2.4/2.4
Viribans 
streptococci 5.2/5.8/4.2/3.5
Bacteroides spp. 9.7/4.7/5.0/3.1
aAbbreviations: BSI = bloodstream infection; RTI = respiratory tract infection; UTI = urinary tract infection; SSI = surgical site infection; CoNS = coagulase-negative staphylococci;
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Discussion
Hospitals worldwide are continuing to face the crisis
of the upsurge and dissemination of antimicrobial-resistant
bacteria, particularly those causing nosocomial infections in
ICU patients (1,27-29). Among resistant bacteria, MRSA,
MRCoNS, VRE, third-generation cephalosporin-resistant
Enterobacteriaceae, and imipenem- or ciprofloxacin-resistant
P. aeruginosa and A. baumannii are of great concern because
these bacteria have spread worldwide and ultimately will com-
promise the antimicrobial therapy of infections caused by these
organisms (2,25-28,30).
This report describes trends in major nosocomial pathogens
and shifts in antimicrobial resistance during a 19-year period in
a large teaching hospital in Taiwan. In a comparison of data
from a recent NNIS study and other surveillance systems
(2,4,9,31), our results suggest four conclusions. First, Candida
species, rather than P. aeruginosa, E. coli, or staphylococci,
now are the most frequent pathogens causing overall nosoco-
mial infections and BSIs in this hospital. The upward trend in
coagulase-negative staphylococci, which was the leading cause
of BSI in the recent NNIS study, was not confirmed in our
study. Second, we observed a remarkably high incidence of
MRSA, especially in ICUs, contrasted with a relatively low
incidence of VRE. Third, we report an increase in incidence of
cefotaxime-resistant Enterobacteriaceae, especially in the inci-
dence of cefotaxime-resistant K. pneumoniae in ICUs. Fourth,
although the overall incidence of imipenem resistance among
P. aeruginosa and A. baumannii in recent years has remained
Table 2. Selected antimicrobial resistant pathogens associated with nosocomial infection at National Taiwan University Hospital from 1981 to
1999
Resistant pathogen % resistance (all patients/in intensive care unit patients/in patients in general wards)
1981-1986 1987-1992 1993-1998 1999
Methicillin-resistant Staphylococcus 
aureus 20.2/27.8/19.5 31.4/58.5/26.6 64.8/86.9/56.7 69.3/87.4/60.2
Methicillin-resistant CoNSa 72.2/88.2/70.8 74.0/83.9/71.5 79.0/88.7/75.1 90.6/90.9/90.5
Penicillin-resistant enterococci 5.9/6.8/5.8 20.7/30/19.6 19.5/22.6/18.7 35.9/40.9/27.8
Gentamicin-resistant enterococci 0.0/0.0/0.0 71.0/71.4/70.9 61.5/67.2/60.0 50.0/39.3/55.2
Cefotaxime-resistant Escherichia coli 1.6/0.0/1.7 2.8/8.6/2.5 6.8/13.1/6.2 12.3/10.3/12.7
Cefotaxime-resistant Klebsiella 
pneumoniae 4.9/8.8/3.9 7.4/16.9/5.6 22.8/50.5/15.6 16.5/40.0/9.3
Cefotaxime-resistant Enterobacter spp. 35.8/52.4/32.4 49.7/55.7/47.7 57.6/67.0/53.6 50.9/61.8/46.2
Cefotaxime-resistant Pseudomonas 
aeruginosa 24.2/20.0/25.0 16.1/24.3/12.1 10.2/16.9/7.8 11.2/17.6/8.1
Imipenem-resistant P. aeruginosa NA NA 8.5/18.2/4.9 6.7/4.5/7.7
Ciprofloxacin-resistant P. aeruginosa NA NA 8.7/11.6/5.8 14.0/18.2/2.9
Imipenem-resistant Acinetobacter 
baumannii NA NA 6.7/9.1/4.4 12.5/23.3/7.6
aCoNS = coagulase-negative staphylococci; NA = not available.
Figure 2. Changes in major antimicrobial-resistant nosocomial patho-
gens in relation to ceftazidime use at National Taiwan University Hospi-
tal from 1991 to 1999. 
Figure 3. Incidences of vancomycin-resistant enterococci (VRE) among
all enterococcal isolates causing nosocomial infections in relation to
vancomycin use at National Taiwan University Hospital, 1995-1999.
Numbers above the bars denote the number of enterococcal isolates
causing nosocomial infections. Numbers within the bars denote the
numbers of VRE.Emerging Infectious Diseases  •  Vol. 8, No. 1, January 2002 67
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stable (4% to 11%), higher incidences of imipenem-resistant P.
aeruginosa or A. baumannii were found in ICUs than in gen-
eral wards in most time periods. 
Since 1990,  Candida species have continued to be an
important cause of nosocomial BSI in the United States, and
the proportion (40%-50%) of these infections due to species of
Candida other than  C. albicans may be increasing
(12,19,20,31,32). Among the species of Candida other than C.
albicans, C. glabrata (prone to be resistant to fluconazole) and
C. krusei (intrinsically resistant to fluconazole) are of clinical
importance (31,33). Although the proportion (40%) of candi-
demia due to non-albicans Candida species in 1999 in our hos-
pital was similar to that (48%) reported in the United States
from April 1995 to June 1996, the incidences of C. glabrata
(8.8%) and  C. krusei (0%) in our hospital were lower than
those (20% and 5%, respectively) in the United States (31). 
Although an upsurge in the incidences of K. pneumoniae
and E. coli isolates resistant to cefotaxime was noted in our
ICUs, an investigation is under way into the mechanisms of
resistance and potential outbreaks (clonal dissemination or
gene transfer) (34). The abrupt increase in the proportion of A.
baumannii isolates resistant to imipenem in 1999 resulted from
wide dissemination of several multidrug-resistant clones in
ICUs and many general wards in the hospital (data not shown). 
In summary, surveillance of the microbial etiology of
nososcomial infections over prolonged time periods not only
can provide important information for day-to-day decision
making in antimicrobial therapy in individual hospitals but
also can reflect local trends and shifts in etiology and antimi-
crobial drug resistance. Nosocomial pathogens have shifted
away from easily treated bacteria toward more resistant bacte-
ria and even to Candida species with fewer options for therapy.
These shifts continue to present challenges for nosocomial
infection control and prevention. 
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